CG Oncology, Inc. CGON
78.94 USD -5.84 (-6.89%)
Regular-session close
79.00 +0.06 +0.08%
After hours · Nov 17, 5:12 PM ET
73.00 Day range 83.97
37.01 52-week range 93.95
- YTD
- +90.13%
- 1 year
- +91.37%
News
benzinga.com JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $113 JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $96 to $113.
benzinga.com Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $100 Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $85 to $100.
benzinga.com RBC Capital Downgrades CG Oncology to Sector Perform, Raises Price Target to $97 RBC Capital analyst Leonid Timashev downgrades CG Oncology (NASDAQ:CGON) from Outperform to Sector Perform and raises the price target from $80 to $97.
benzinga.com United Natural Foods To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts raised price targets for CG Oncology, Viatris, Rubrik, Allarity, IDACORP, Tyson Foods and Range Resources.benzinga.com Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $91 Wedbush analyst Robert Driscoll maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $84 to $91.
benzinga.com HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $115 HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $100 to $115.
benzinga.com CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds CG Oncology Inc. (NASDAQ:CGON) on Monday announced positive topline results from its Phase 3 PIVOT-006 trial, which Arthur Kuan, chairman, president, and CEO of CG Oncology, called a defining…
benzinga.com CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds CG Oncology reports Phase 3 data showing cretostimogene cuts bladder cancer recurrence risk by 68%, advancing two 2027 BLA filings.
schaeffersresearch.com 2 Cancer-Drug Developers Seeing Unusual Options Volume Two cancer drug developers are seeing unusual options activity today, with Summit Therapeutics Inc (NASDAQ:SMMT) and CG Oncology Inc (NASDAQ:CGON) moving in opposite directions following major…
benzinga.com Crude Oil Down Over 2%; NY Manufacturing Activity Declines In November U.S. stocks fell Monday as tech slid and manufacturing sentiment weakened; oil, gold and silver also declined, while TELUS and H World surged.
investors.com CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out CG Oncology said Monday its experimental bladder cancer treatment cut the risk of recurrence by 68%. The biotech stock broke out.
benzinga.com H World Group Posts Upbeat Q3 Earnings, Joins CG Oncology, TELUS And Other Big Stocks Moving Higher On Monday U.S. stocks fell, but H World Group surged 9.3% on strong Q3 results and raised guidance; several other stocks posted notable gains.benzinga.com CG Oncology Announces Topline Results From Its Phase 3 PIVOT-006 Trial; Achieved Primary Endpoint With Compelling Safety And Tolerability Results Topline results from PIVOT-006, its Phase 3 registrational trial evaluating adjuvant intravesical cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC,…
globenewswire.com PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC) – Cretostimogene reduced the risk of recurrence by 68%, demonstrating a statistically significant and clinically meaningful benefit with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; pbenzinga.com Guggenheim Maintains Buy on CG Oncology, Lowers Price Target to $89 Guggenheim analyst Michael Schmitz maintains CG Oncology (NASDAQ:CGON) with a Buy and lowers the price target from $90 to $89.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…benzinga.com CG Oncology Q3 EPS $(0.64) Beats $(0.82) Estimate, Sales $1.604M Beat $643.584K Estimate CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 12.28 percent decrease over losses of $(0.57)…
